Real-World Use of Novel Treatments in Patients With Spinal Muscular Atrophy (SMA): A Multi-Site Retrospective Chart Review of Pediatric SMA Patients Outside of the United States
Completed
Conditions studied: Spinal Muscular Atrophy
In brief
This global, retrospective, non-interventional, medical chart review (MCR), descriptive study collected patient-level data in regions outside the US. The study required a repeated data collection at follow-up dates from start of treatment with nusinersen, onasemnogene abeparvovec-xioi (OA), and/or risdiplam. At the start of data collection, the study team reached out to the health care providers (HCPs) involved in treating pediatric SMA patients for participating in this study. The physicians across the participating countries conducted a retrospective MCR of pediatric patients diagnosed with SMA who were treated with at least 1of the 3 novel disease-modifying treatments (DMTs): nusinersen, OA, and/or risdiplam. All health care encounters data i.e., emergency and inpatient admissions, surgery, and outpatient consultations of recruited patients, including their treatment with nusinersen, OA, and/or risdiplam, were abstracted to understand the treatment patterns as per routine clinical practice for SMA management globally. The first date of initial administration of 1 of the 3 target drugs was used as the "index date." Based on this, the record abstraction was performed through a retrospective MCR during the pre-index period, at index date and in the post-index period.
Key facts
- Study ID
- NCT06178393
- Run by
- Novartis Pharmaceuticals
- People needed
- 162
- Starts
- 2022-05-05
- Expected to finish
- 2022-12-30
- Last updated by the study team
- 2023-12-21
Who can join
Age: any, up to 5. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Genetically confirmed diagnosis of SMA.
- Aged less than 5 years at index date.
- Initiated treatment with nusinersen or onasemnogene abeparvovec-xioi or risdiplam or any combination of them during the identification period.
- Availability of medical information in chart for at least 1 visit prior to initiation of treatment with the target treatment(s).
You may not qualify if…
- None
Where it is running
- Novartis — Bannockburn, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.